EMERGENT BIOSOLUTIONS INC. Payment for Contingent Consideration Liability, Investing Activities
EMERGENT BIOSOLUTIONS INC. (EBS) reported Payment for Contingent Consideration Liability, Investing Activities of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities · last filed 2024-11-07
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for the quarter ending 2023-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for the quarter ending 2022-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for the quarter ending 2021-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for the quarter ending 2021-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for fiscal 2023 was $6.30M.
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for fiscal 2022 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. payment for contingent consideration liability, investing activities for fiscal 2020 was $10.00M, a 0.00% change from fiscal 2019.
| Period end | Payment for Contingent Consideration Liability, Investing Activities 3 month | Payment for Contingent Consideration Liability, Investing Activities 6 month | Payment for Contingent Consideration Liability, Investing Activities 9 month | Payment for Contingent Consideration Liability, Investing Activities 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $6.30M 10-K · filed 2024-03-08 | ||
| 2023-09-30 | $6.30M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 10-K · filed 2024-03-08 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-12-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-08 | $0.00 10-K · filed 2024-03-08 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-07-30 | |||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $0.00 derived: sum of 2 quarters · filed 2023-12-11 | $10.00M 10-K/A · filed 2023-12-11 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $10.00M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $10.00M 10-Q · filed 2021-07-30 | |||
| 2019-12-31 | $10.00M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |